These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
205 related articles for article (PubMed ID: 15910404)
1. Simvastatin effects in normo- and hypercholesterolaemic patients with peripheral arterial occlusive disease: a pilot study. Grodzińska L; Starzyk D; Bieroń K; Goszcz A; Korbut R Basic Clin Pharmacol Toxicol; 2005 Jun; 96(6):413-9. PubMed ID: 15910404 [TBL] [Abstract][Full Text] [Related]
2. Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial. Stender S; Schuster H; Barter P; Watkins C; Kallend D; Diabetes Obes Metab; 2005 Jul; 7(4):430-8. PubMed ID: 15955130 [TBL] [Abstract][Full Text] [Related]
3. Effects of simvastatin withdrawal on serum matrix metalloproteinases in hypercholesterolaemic patients. Huang CY; Wu TC; Lin WT; Leu HB; Lin CP; Lin SJ; Chen JW Eur J Clin Invest; 2006 Feb; 36(2):76-84. PubMed ID: 16436088 [TBL] [Abstract][Full Text] [Related]
4. Antioxidant effect of simvastatin is not enhanced by its association with alpha-tocopherol in hypercholesterolemic patients. Pereira EC; Bertolami MC; Faludi AA; Sevanian A; Abdalla DS Free Radic Biol Med; 2004 Nov; 37(9):1440-8. PubMed ID: 15454283 [TBL] [Abstract][Full Text] [Related]
5. Effect of low-density lipoprotein apheresis on patients with peripheral arterial disease. Peripheral Arterial Disease LDL Apheresis Multicenter Study (P-LAS). Tsuchida H; Shigematsu H; Ishimaru S; Iwai T; Akaba N; Umezu S Int Angiol; 2006 Sep; 25(3):287-92. PubMed ID: 16878078 [TBL] [Abstract][Full Text] [Related]
6. Treatment with L-arginine is likely to stimulate generation of nitric oxide in patients with peripheral arterial obstructive disease. Gryglewski RJ; Grodzińska L; Kostka-Trabka E; Korbut R; Bieroón K; Goszcz A; Sławiński M Wien Klin Wochenschr; 1996; 108(4):111-6. PubMed ID: 8867484 [TBL] [Abstract][Full Text] [Related]
7. No effect of lipid lowering on platelet activity in patients with coronary artery disease and type 2 diabetes or impaired glucose tolerance. Malmström RE; Settergren M; Böhm F; Pernow J; Hjemdahl P Thromb Haemost; 2009 Jan; 101(1):157-64. PubMed ID: 19132203 [TBL] [Abstract][Full Text] [Related]
8. Tolerability and effects on lipids of ezetimibe coadministered with pravastatin or simvastatin for twelve months: results from two open-label extension studies in hypercholesterolemic patients. Strony J; Hoffman R; Hanson M; Veltri E Clin Ther; 2008 Dec; 30(12):2280-97. PubMed ID: 19167588 [TBL] [Abstract][Full Text] [Related]
9. Clinical experience with ezetimibe/simvastatin in a Mediterranean population. Migdalis I; Efthimiadis A; Pappas S; Alexopoulos D; Vlasserou F; Mikhailidis DP Curr Med Res Opin; 2009 Oct; 25(10):2571-6. PubMed ID: 19739939 [TBL] [Abstract][Full Text] [Related]
10. Beneficial effects of atorvastatin on sd LDL and LDL phenotype B in statin-naive patients and patients previously treated with simvastatin or pravastatin. Baldassarre S; Scruel O; Deckelbaum RJ; Dupont IE; Ducobu J; Carpentier YA Int J Cardiol; 2005 Oct; 104(3):338-45. PubMed ID: 16186066 [TBL] [Abstract][Full Text] [Related]
11. Effects of simvastatin and pravastatin on peroxidation of erythrocyte plasma membrane lipids in patients with type 2 hypercholesterolemia. Koter M; Franiak I; Broncel M; Chojnowska-Jezierska J Can J Physiol Pharmacol; 2003 May; 81(5):485-92. PubMed ID: 12774855 [TBL] [Abstract][Full Text] [Related]
12. Effects of simvastatin on pro-inflammatory cytokines in patients with hypercholesterolemia. Zubelewicz-Szkodzińska B; Szkodziński J; Danikiewicz A; Romanowski W; Błazelonis A; Muc-Wierzgon M; Pietka-Rzycka A; Muryn Z Kardiol Pol; 2003 Dec; 59(12):465-74. PubMed ID: 14724693 [TBL] [Abstract][Full Text] [Related]
13. Co-administration of ezetimibe and simvastatin in acute myocardial infarction. Chenot F; Montant PF; Marcovitch O; Blaimont M; de Meester A; Descamps OS Eur J Clin Invest; 2007 May; 37(5):357-63. PubMed ID: 17461981 [TBL] [Abstract][Full Text] [Related]
14. The effects of low-dose simvastatin and ezetimibe compared to high-dose simvastatin alone on post-fat load endothelial function in patients with metabolic syndrome: a randomized double-blind crossover trial. Olijhoek JK; Hajer GR; van der Graaf Y; Dallinga-Thie GM; Visseren FL J Cardiovasc Pharmacol; 2008 Aug; 52(2):145-50. PubMed ID: 18670365 [TBL] [Abstract][Full Text] [Related]
15. Effects of ezetimibe/simvastatin on lipoprotein subfractions in patients with primary hypercholesterolemia: an exploratory analysis of archived samples using two commercially available techniques. Ose L; Reyes R; Johnson-Levonas AO; Sapre A; Tribble DL; Musliner T Clin Ther; 2007 Nov; 29(11):2419-32. PubMed ID: 18158082 [TBL] [Abstract][Full Text] [Related]
16. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice. Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658 [TBL] [Abstract][Full Text] [Related]
17. Effects of exercise rehabilitation on cardiovascular risk factors in older patients with peripheral arterial occlusive disease. Izquierdo-Porrera AM; Gardner AW; Powell CC; Katzel LI J Vasc Surg; 2000 Apr; 31(4):670-7. PubMed ID: 10753274 [TBL] [Abstract][Full Text] [Related]
18. Effects of simvastatin on plasma antioxidant status and vitamins in hypercholesterolemic patients. Shin MJ; Chung N; Lee JH; Jang Y; Park E; Jeon KI; Chung JH; Seo BY Int J Cardiol; 2007 May; 118(2):173-7. PubMed ID: 17005272 [TBL] [Abstract][Full Text] [Related]
19. The influence of atorvastatin on walking performance in peripheral arterial disease. Bregar U; Poredos P; Sabovic M; Jug B; Sebestjen M Vasa; 2009 May; 38(2):155-9. PubMed ID: 19588303 [TBL] [Abstract][Full Text] [Related]